Vol. 40 No. 5 (2023): Octubre
Original Article

Prevalence and characterization of cancer in people living with HIV in Colombia

Leonardo Arevalo Mora
Centro de Expertos Para la Atención Integral- CEPAIN, Bogotá, Colombia
Ernesto Martínez-Buitrago
Facultad de Medicina, Universidad del Valle, Cali, Colombia
María Paulina Posada
Corporación para Investigaciones Biológicas, Medellín,
Sandra Liliana Valderrama-Beltrán
Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá,
Sandra Segura
Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá,
Martha Milena García
SIES, Armenia
Otto Sussmann
Asistencia Científica de Alta Complejidad SAS, Bogotá
Beatriz Hernández
Infectoclínicos SAS, Bogotá
Javier Andrade
Infectoclínicos SAS, Bogotá
William Lenis
Recuperar SA, Cali
Mónica Mantilla
Centro de Expertos Para la Atención Integral- CEPAIN, Bogotá,
Claudia González
SIES, Cali,
Julieta Franco
SIES, Pereira
Ximena Galindo
Corporación de Lucha Contra el SIDA, Cali
Héctor Fabio Mueses
Corporación de Lucha Contra el SIDA, Cali
Juan Carlos Álzate- Ángel
Corporación para Investigaciones Biológicas, Medellín
Norberto Fonseca
Asistencia Científica de Alta Complejidad SAS, Bogotá
Bio
Olga García Duque
Centro de Expertos Para la Atención Integral- CEPAIN, Armenia
Olga Ramos
Centro de Expertos Para la Atención Integral- CEPAIN, Neiva
Leonardo Montero
TodoMed Cali
Angela Cuartas
Centro de Expertos Para la Atención Integral- CEPAIN, Manizales
José Antonio Pardo
Centro de Expertos Para la Atención Integral- CEPAIN, Cali
Kevin Escandón
University of Minnesota, Minneapolis, MN, US
Bio

Published 2023-10-12

How to Cite

1.
Arevalo Mora L, Martínez-Buitrago E, Posada MP, Valderrama-Beltrán SL, Segura S, García MM, Sussmann O, Hernández B, Andrade J, Lenis W, Mantilla M, González C, Franco J, Galindo X, Mueses HF, Álzate- Ángel JC, Fonseca N, García Duque O, Ramos O, Montero L, Cuartas A, Pardo JA, Escandón K. Prevalence and characterization of cancer in people living with HIV in Colombia. Rev. Chilena. Infectol. [Internet]. 2023 Oct. 12 [cited 2025 Nov. 4];40(5). Available from: https://revinf.cl/index.php/revinf/article/view/1765

Abstract

Background: In the acquired immunodeficiency syndrome, neoplasms have played a preponderant role, and with the advent of antiretroviral treatment (ART), HIV has become a chronic disease, with malignant tumors being an important cause of morbidity and mortality. Aim: To describe the demographic, clinical, and laboratory characteristics of people living with HIV who have been diagnosed with cancer in Colombia and to compare the groups of AIDS-defining (ADC) and non-AIDS-defining neoplasms (NADC). Methods: Retrospective, multicenter study that included people living with HIV/AIDS (PLWHA) diagnosed with malignancies treated at 23 HIV care centers located in 11 Colombian cities from 1986 to 2018. Data related to HIV infection and cancer diagnosis were collected and analyzed. Results: Among 23,189 patients, 650 malignancy cases were identified (prevalence of 2.8% [95% CI 2.6–2.9]). AIDS-defining neoplasm remains the most prevalent type of cancer (71.1%), The most frequent individual malignancies were Kaposi sarcoma (n: 330; 50.8%), non-Hodgkin lymphoma (n: 110; 16.9%), skin cancer (n: 48; 7.4%), and Hodgkin lymphoma (n: 25; 3.8%). Compared people with NADC, with ADC were more likely to be MSM and have a CDC HIV stage 3, CD4 T cell count < 200/µL, and HIV viral load ≥ 50 copies/mL at the time of malignancy diagnosis. PLWHA and with NADC were significantly older and were more likely to be smokers. Conclusions: These findings are relevant considering the increasing burden of cancer in the aging PLWHA and the changing causes of morbidity and mortality. Late presentation to HIV care and delayed ART initiation are likely factors contributing to the slower shift toward NADCs compared with high-income regions where access to ART is better. Knowledge of the current epidemiological trends and profile of cancer in PLWHA is critical to improve cancer prevention and treatment efforts in the context of comprehensive HIV care.